Liquidia (LQDA) Projected to Post Earnings on Monday

Liquidia (NASDAQ:LQDA) is anticipated to post its Q3 2026 results before the market opens on Monday, November 2nd. Analysts expect the company to post earnings of $0.96 per share and revenue of $214.18 million for the quarter. Investors can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Monday, November 2, 2026 at 8:30 AM ET.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Wednesday, August 12th. The company reported $0.74 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.76 by ($0.02). The business had revenue of $171.68 million for the quarter, compared to analysts’ expectations of $168.48 million. Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The firm’s revenue was up 1842.1% on a year-over-year basis. During the same period in the prior year, the company posted ($0.49) EPS. On average, analysts expect Liquidia to post $2.05 EPS for the current fiscal year and $2.13 EPS for the next fiscal year.

Liquidia Stock Up 0.2%

LQDA stock opened at $45.06 on Friday. The company has a market cap of $4.03 billion, a price-to-earnings ratio of 32.84, a PEG ratio of 0.39 and a beta of 0.61. The company has a current ratio of 2.31, a quick ratio of 2.12 and a debt-to-equity ratio of 0.63. Liquidia has a 12 month low of $22.21 and a 12 month high of $93.61. The firm has a 50-day moving average of $52.99 and a two-hundred day moving average of $54.30.

Analyst Ratings Changes

LQDA has been the topic of a number of analyst reports. Needham & Company LLC reduced their price objective on Liquidia from $72.00 to $58.00 and set a “buy” rating on the stock in a research report on Wednesday, October 14th. Piper Sandler set a $129.00 price objective on shares of Liquidia in a report on Friday, July 24th. Lifesci Capital raised shares of Liquidia from a “hold” rating to an “outperform” rating and set a $59.00 price objective for the company in a report on Wednesday, October 14th. HC Wainwright raised their price objective on shares of Liquidia from $58.00 to $65.00 and gave the stock a “buy” rating in a research report on Thursday, October 15th. Finally, Wells Fargo & Company lifted their target price on shares of Liquidia from $30.00 to $33.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 14th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Liquidia currently has a consensus rating of “Hold” and a consensus target price of $72.85.

Insider Activity at Liquidia

In related news, insider Jason Adair sold 688 shares of the business’s stock in a transaction dated Monday, October 26th. The shares were sold at an average price of $43.19, for a total value of $29,714.72. Following the sale, the insider directly owned 177,269 shares in the company, valued at approximately $7,656,248.11. The trade was a 0.39% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Scott Moomaw sold 8,863 shares of the business’s stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $28.48, for a total transaction of $252,418.24. Following the completion of the sale, the insider owned 181,487 shares in the company, valued at approximately $5,168,749.76. This trade represents a 4.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 566,579 shares of company stock valued at $25,746,120 over the last 90 days. Corporate insiders own 25.60% of the company’s stock.

About Liquidia

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with pulmonary hypertension and other serious cardiopulmonary diseases. The company is headquartered in Research Triangle Park, North Carolina, and uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition for inhaled and injectable medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder formulation of treprostinil delivered through a proprietary inhaler.